Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | DRD3 | P35462 | 6/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL15796096 | 0.80 | ESR2 (0.33) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL14240535 | 0.77 | DRD2 (0.38) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL25949682 | 0.76 | EPAS1 (0.33) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL20739385 | 0.76 | CETP (0.34) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL6938167 | 0.74 | DRD2 (0.34) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL6740755 | 0.73 | ALDH1A1 (0.41) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7030271 | 0.73 | DRD2 (0.32) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30487004 | 0.72 | ADORA1 (0.33) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL11701524 | 0.72 | ADORA1 (0.31) | — | |
| SCHEMBL17864633 | 0.71 | MEN1 (0.41) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | TPO, THOP1, THRB | DRD2 3184/4885DRD3 3275/4885DRD4 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.